Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables

Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via “danger signals”. The recent phase II “GBM-Vax” trial showed no clinical efficacy for Aude...

Descripción completa

Detalles Bibliográficos
Autores principales: Erhart, Friedrich, Buchroithner, Johanna, Reitermaier, René, Fischhuber, Katrin, Klingenbrunner, Simone, Sloma, Ido, Hibsh, Dror, Kozol, Renana, Efroni, Sol, Ricken, Gerda, Wöhrer, Adelheid, Haberler, Christine, Hainfellner, Johannes, Krumpl, Günther, Felzmann, Thomas, Dohnal, Alexander M., Marosi, Christine, Visus, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280511/
https://www.ncbi.nlm.nih.gov/pubmed/30518425
http://dx.doi.org/10.1186/s40478-018-0621-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280511/
https://www.ncbi.nlm.nih.gov/pubmed/30518425
http://dx.doi.org/10.1186/s40478-018-0621-2

Ejemplares similares